Swedish Orphan Biovitrum AB (publ) EPS Estimated At $0.21 as of July, 18

June 27, 2018 - By Lena Young

Swedish Orphan Biovitrum AB (OTCMKTS:publ) Corporate Logo

Swedish Orphan Biovitrum AB (OTCMKTS:publ)’s earnings release is anticipated by WallStreet on July, 18, Faxor reports. SWTUY’s profit could be $57.46M with 25.65 P/E in case $0.21 EPS is revealed. Wall Street predicts -12.50 % negative EPS growth as of July, 18. publ is touching $21.55 during the last trading session, after decreased 2.36%.Swedish Orphan Biovitrum AB has 965 shares volume, 315.95% up from normal. publ is and has moved 0.00% since June 27, 2017. publ underperformed by 12.57% the S&P500.

Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, makes, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Sweden and internationally.The firm is worth $5.90 billion. The Company’s core products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; and Xiapex for the treatment of Dupuytren's contracture and Peyronie's disease.35.5 is the P/E ratio. The firm also offers Elocta and Alprolix for the treatment of haemophilia; and Ammonaps, Ammonul, and Ravicti for use in the genetics and metabolism diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.